[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgu2KxlKfLRxEuxgfiUEPEDjKmWRmjRTSIRWPuvAe05o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"Vejle Hospital",[4],92,false,21,6,20823,8,55,[14,17,19,22,25,27,29,32],{"name":15,"count":16},"Colorectal Cancer",10,{"name":18,"count":11},"Breast Cancer",{"name":20,"count":21},"Ovarian Cancer",7,{"name":23,"count":24},"Multiple Myeloma",5,{"name":26,"count":24},"Metastatic Colorectal Cancer",{"name":28,"count":24},"Myopia",{"name":30,"count":31},"Cancer",4,{"name":33,"count":31},"Rectal Cancer",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT01918527","Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer","2023-06","Capecitabine",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04245865","Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer","2025-03-31","Fluorouracil",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06473701","Reducing Breathlessness With Dronabinol in COPD Patients","2026-09","Dronabinol 2.5mg",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT04095299","Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients","2026-12","Capecitabine 825 mg\u002Fm2 twice daily on weekdays",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06714123","Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease","2028-12","Senicapoc",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,125,155,180,202,255,277,295,313,338,363,381,406,445,467,485,517,535,553,571,589,607,630,686,720,747,776,809,836,858,886,910,928,946,969,997,1015,1033,1051,1073,1091,1119,1137,1155,1173,1191,1209,1227,1245,1263,1281,1304,1329,1347,1373],{"intervention":69,"totalTrials":31,"cells":70},"Oxaliplatin",{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":113,"PHASE4":121,"NA":123},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":112,"soonestReadout":43},[78,91,103],{"nctId":79,"briefTitle":80,"status":81,"phases":82,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"NCT01108107","Neoadjuvant Treatment of Colon Cancer","COMPLETED",[63],"2013-09","2015-03","2010-04",76,[88],"Colon Cancer",[69,39,69,39,90],"Panitumumab",{"nctId":92,"briefTitle":93,"status":81,"phases":94,"primaryCompletion":95,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":100},"NCT01206049","Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations",[63],"2016-03","2010-09",88,[99],"Cholangiocarcinoma",[101,69,39,90,102],"Gemcitabine","Bevacizumab",{"nctId":41,"briefTitle":42,"status":104,"phases":105,"primaryCompletion":43,"completion":53,"start":106,"enrollment":107,"conditions":108,"interventions":110},"ACTIVE_NOT_RECRUITING",[63],"2020-06-26",83,[109],"Colorectal Cancer Metastatic",[44,111,69,102,39],"Calcium folinate",1,{"trials":114,"activeCount":112,"soonestReadout":38},[115],{"nctId":36,"briefTitle":37,"status":104,"phases":116,"primaryCompletion":38,"completion":117,"start":83,"enrollment":118,"conditions":119,"interventions":120},[64],"2026-06",250,[88],[39,69],{"trials":122,"activeCount":73},[],{"trials":124,"activeCount":73},[],{"intervention":39,"totalTrials":31,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":145,"PHASE4":151,"NA":153},{"trials":128,"activeCount":73},[],{"trials":130,"activeCount":73},[],{"trials":132,"activeCount":112,"soonestReadout":43},[133,137,141],{"nctId":79,"briefTitle":80,"status":81,"phases":134,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":135,"interventions":136},[63],[88],[69,39,69,39,90],{"nctId":92,"briefTitle":93,"status":81,"phases":138,"primaryCompletion":95,"completion":95,"start":96,"enrollment":97,"conditions":139,"interventions":140},[63],[99],[101,69,39,90,102],{"nctId":41,"briefTitle":42,"status":104,"phases":142,"primaryCompletion":43,"completion":53,"start":106,"enrollment":107,"conditions":143,"interventions":144},[63],[109],[44,111,69,102,39],{"trials":146,"activeCount":112,"soonestReadout":38},[147],{"nctId":36,"briefTitle":37,"status":104,"phases":148,"primaryCompletion":38,"completion":117,"start":83,"enrollment":118,"conditions":149,"interventions":150},[64],[88],[39,69],{"trials":152,"activeCount":73},[],{"trials":154,"activeCount":73},[],{"intervention":49,"totalTrials":112,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":176,"NA":178},{"trials":158,"activeCount":73},[],{"trials":160,"activeCount":73},[],{"trials":162,"activeCount":73},[],{"trials":164,"activeCount":112,"soonestReadout":48},[165],{"nctId":46,"briefTitle":47,"status":166,"phases":167,"primaryCompletion":48,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":175},"RECRUITING",[64],"2026-10","2025-02-26",30,[172,173,174],"COPD","Breathlessness","Cannabis",[49],{"trials":177,"activeCount":73},[],{"trials":179,"activeCount":73},[],{"intervention":54,"totalTrials":112,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":198,"NA":200},{"trials":183,"activeCount":73},[],{"trials":185,"activeCount":73},[],{"trials":187,"activeCount":73},[],{"trials":189,"activeCount":112,"soonestReadout":53},[190],{"nctId":51,"briefTitle":52,"status":166,"phases":191,"primaryCompletion":53,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},[64],"2033-12","2020-01-20",162,[196],"Cancer of Rectum",[54],{"trials":199,"activeCount":73},[],{"trials":201,"activeCount":73},[],{"intervention":102,"totalTrials":24,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":205,"activeCount":73},[],{"trials":207,"activeCount":73},[],{"trials":209,"activeCount":112,"soonestReadout":43},[210,214,223,234,245],{"nctId":92,"briefTitle":93,"status":81,"phases":211,"primaryCompletion":95,"completion":95,"start":96,"enrollment":97,"conditions":212,"interventions":213},[63],[99],[101,69,39,90,102],{"nctId":215,"briefTitle":216,"status":81,"phases":217,"primaryCompletion":218,"completion":218,"start":84,"enrollment":219,"conditions":220,"interventions":221},"NCT02399592","Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer",[63],"2019-07",23,[20],[102,222],"Tocotrinol",{"nctId":224,"briefTitle":225,"status":81,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":232},"NCT00744718","Bevacizumab and Carboplatin for Patients With Ovarian Cancer",[63],"2015-08","2015-12","2008-08",73,[20],[102,233],"Carboplatin",{"nctId":235,"briefTitle":236,"status":81,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT04175470","Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer",[63],"2024-07-30","2024-12-31","2019-10-29",20,[243],"Ovarian Cancer Recurrent",[102],{"nctId":41,"briefTitle":42,"status":104,"phases":246,"primaryCompletion":43,"completion":53,"start":106,"enrollment":107,"conditions":247,"interventions":248},[63],[109],[44,111,69,102,39],{"trials":250,"activeCount":73},[],{"trials":252,"activeCount":73},[],{"trials":254,"activeCount":73},[],{"intervention":59,"totalTrials":112,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":258,"activeCount":73},[],{"trials":260,"activeCount":73},[],{"trials":262,"activeCount":112,"soonestReadout":58},[263],{"nctId":56,"briefTitle":57,"status":166,"phases":264,"primaryCompletion":58,"completion":58,"start":265,"enrollment":266,"conditions":267,"interventions":270},[63],"2025-08-01",140,[268,269],"Pulmonary Fibrosis, Interstitial Lung Disease","Idiopathic Pulmonary Fibrosis",[59],{"trials":272,"activeCount":73},[],{"trials":274,"activeCount":73},[],{"trials":276,"activeCount":73},[],{"intervention":44,"totalTrials":112,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":280,"activeCount":73},[],{"trials":282,"activeCount":73},[],{"trials":284,"activeCount":112,"soonestReadout":43},[285],{"nctId":41,"briefTitle":42,"status":104,"phases":286,"primaryCompletion":43,"completion":53,"start":106,"enrollment":107,"conditions":287,"interventions":288},[63],[109],[44,111,69,102,39],{"trials":290,"activeCount":73},[],{"trials":292,"activeCount":73},[],{"trials":294,"activeCount":73},[],{"intervention":111,"totalTrials":112,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":307,"PHASE4":309,"NA":311},{"trials":298,"activeCount":73},[],{"trials":300,"activeCount":73},[],{"trials":302,"activeCount":112,"soonestReadout":43},[303],{"nctId":41,"briefTitle":42,"status":104,"phases":304,"primaryCompletion":43,"completion":53,"start":106,"enrollment":107,"conditions":305,"interventions":306},[63],[109],[44,111,69,102,39],{"trials":308,"activeCount":73},[],{"trials":310,"activeCount":73},[],{"trials":312,"activeCount":73},[],{"intervention":314,"totalTrials":112,"cells":315},"Ropivacaine, Ketorolac and Adrenalin",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":336},{"trials":317,"activeCount":73},[],{"trials":319,"activeCount":73},[],{"trials":321,"activeCount":73},[],{"trials":323,"activeCount":73},[],{"trials":325,"activeCount":73},[326],{"nctId":327,"briefTitle":328,"status":81,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT00603083","Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia",[65],"2008-10","2008-01",60,[334],"Pain, Postoperative",[314],{"trials":337,"activeCount":73},[],{"intervention":339,"totalTrials":112,"cells":340},"Buprenorphine",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":361},{"trials":342,"activeCount":73},[],{"trials":344,"activeCount":73},[],{"trials":346,"activeCount":73},[],{"trials":348,"activeCount":73},[],{"trials":350,"activeCount":73},[351],{"nctId":352,"briefTitle":353,"status":81,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":86,"conditions":358,"interventions":359},"NCT00964808","Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur",[65],"2013-05","2013-08","2009-09",[334],[339,360],"Oxycodone",{"trials":362,"activeCount":73},[],{"intervention":360,"totalTrials":112,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":379},{"trials":366,"activeCount":73},[],{"trials":368,"activeCount":73},[],{"trials":370,"activeCount":73},[],{"trials":372,"activeCount":73},[],{"trials":374,"activeCount":73},[375],{"nctId":352,"briefTitle":353,"status":81,"phases":376,"primaryCompletion":355,"completion":356,"start":357,"enrollment":86,"conditions":377,"interventions":378},[65],[334],[339,360],{"trials":380,"activeCount":73},[],{"intervention":382,"totalTrials":112,"cells":383},"Dexamethasone 24 mg",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":404},{"trials":385,"activeCount":73},[],{"trials":387,"activeCount":73},[],{"trials":389,"activeCount":73},[],{"trials":391,"activeCount":73},[],{"trials":393,"activeCount":73},[394],{"nctId":395,"briefTitle":396,"status":81,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT05563155","Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response",[65],"2024-03-22","2021-11-01",110,[402],"Post Operative Pain, Acute",[382],{"trials":405,"activeCount":73},[],{"intervention":407,"totalTrials":408,"cells":409},"Lenalidomide",2,{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":430,"PHASE4":441,"NA":443},{"trials":411,"activeCount":73},[],{"trials":413,"activeCount":73},[],{"trials":415,"activeCount":73},[416],{"nctId":417,"briefTitle":418,"status":81,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT01481194","ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma",[63],"2014-05","2018-08-28","2011-11",35,[23],[426,427,407,428,429],"Doxorubicin","Bortezomib","Dexamethasone","Cyclophosphamide",{"trials":431,"activeCount":73},[432],{"nctId":433,"briefTitle":434,"status":81,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":31,"conditions":438,"interventions":439},"NCT02419118","\"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab \"",[63,64],"2015-10-01","2015-01",[23],[440,407,428],"Daratumumab",{"trials":442,"activeCount":73},[],{"trials":444,"activeCount":73},[],{"intervention":428,"totalTrials":408,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":457,"PHASE4":463,"NA":465},{"trials":448,"activeCount":73},[],{"trials":450,"activeCount":73},[],{"trials":452,"activeCount":73},[453],{"nctId":417,"briefTitle":418,"status":81,"phases":454,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":455,"interventions":456},[63],[23],[426,427,407,428,429],{"trials":458,"activeCount":73},[459],{"nctId":433,"briefTitle":434,"status":81,"phases":460,"primaryCompletion":436,"completion":436,"start":437,"enrollment":31,"conditions":461,"interventions":462},[63,64],[23],[440,407,428],{"trials":464,"activeCount":73},[],{"trials":466,"activeCount":73},[],{"intervention":440,"totalTrials":112,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":481,"NA":483},{"trials":470,"activeCount":73},[],{"trials":472,"activeCount":73},[],{"trials":474,"activeCount":73},[],{"trials":476,"activeCount":73},[477],{"nctId":433,"briefTitle":434,"status":81,"phases":478,"primaryCompletion":436,"completion":436,"start":437,"enrollment":31,"conditions":479,"interventions":480},[63,64],[23],[440,407,428],{"trials":482,"activeCount":73},[],{"trials":484,"activeCount":73},[],{"intervention":486,"totalTrials":112,"cells":487},"Day 1: Cisplatin 75 mg\u002Fm2",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":513,"NA":515},{"trials":489,"activeCount":73},[],{"trials":491,"activeCount":73},[],{"trials":493,"activeCount":73},[],{"trials":495,"activeCount":73},[496],{"nctId":497,"briefTitle":498,"status":499,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT02644252","Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer","TERMINATED",[64],"2019-05-09","2021-01-15","2016-01",79,[506],"Lung Cancer",[486,508,509,510,511,512],"Day 1: Vinorelbine 25 mg\u002Fm2","Day 8: Capsule vinorelbine 50 mg\u002Fm2","Day 1: Carboplatin AUC=5","Day 1: Vinorelbine 30 mg\u002Fm2","Day 8: Capsule vinorelbine 60 mg\u002Fm2",{"trials":514,"activeCount":73},[],{"trials":516,"activeCount":73},[],{"intervention":508,"totalTrials":112,"cells":518},{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":531,"NA":533},{"trials":520,"activeCount":73},[],{"trials":522,"activeCount":73},[],{"trials":524,"activeCount":73},[],{"trials":526,"activeCount":73},[527],{"nctId":497,"briefTitle":498,"status":499,"phases":528,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":529,"interventions":530},[64],[506],[486,508,509,510,511,512],{"trials":532,"activeCount":73},[],{"trials":534,"activeCount":73},[],{"intervention":509,"totalTrials":112,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":549,"NA":551},{"trials":538,"activeCount":73},[],{"trials":540,"activeCount":73},[],{"trials":542,"activeCount":73},[],{"trials":544,"activeCount":73},[545],{"nctId":497,"briefTitle":498,"status":499,"phases":546,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":547,"interventions":548},[64],[506],[486,508,509,510,511,512],{"trials":550,"activeCount":73},[],{"trials":552,"activeCount":73},[],{"intervention":510,"totalTrials":112,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":567,"NA":569},{"trials":556,"activeCount":73},[],{"trials":558,"activeCount":73},[],{"trials":560,"activeCount":73},[],{"trials":562,"activeCount":73},[563],{"nctId":497,"briefTitle":498,"status":499,"phases":564,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":565,"interventions":566},[64],[506],[486,508,509,510,511,512],{"trials":568,"activeCount":73},[],{"trials":570,"activeCount":73},[],{"intervention":511,"totalTrials":112,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":585,"NA":587},{"trials":574,"activeCount":73},[],{"trials":576,"activeCount":73},[],{"trials":578,"activeCount":73},[],{"trials":580,"activeCount":73},[581],{"nctId":497,"briefTitle":498,"status":499,"phases":582,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":583,"interventions":584},[64],[506],[486,508,509,510,511,512],{"trials":586,"activeCount":73},[],{"trials":588,"activeCount":73},[],{"intervention":512,"totalTrials":112,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":603,"NA":605},{"trials":592,"activeCount":73},[],{"trials":594,"activeCount":73},[],{"trials":596,"activeCount":73},[],{"trials":598,"activeCount":73},[599],{"nctId":497,"briefTitle":498,"status":499,"phases":600,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":601,"interventions":602},[64],[506],[486,508,509,510,511,512],{"trials":604,"activeCount":73},[],{"trials":606,"activeCount":73},[],{"intervention":608,"totalTrials":112,"cells":609},"Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":626,"NA":628},{"trials":611,"activeCount":73},[],{"trials":613,"activeCount":73},[],{"trials":615,"activeCount":73},[],{"trials":617,"activeCount":73},[618],{"nctId":619,"briefTitle":620,"status":499,"phases":621,"completion":622,"start":623,"enrollment":112,"conditions":624,"interventions":625},"NCT00396487","Tailored Treatment in Metastatic Colorectal Cancer",[64],"2008-02","2006-11",[26],[608],{"trials":627,"activeCount":73},[],{"trials":629,"activeCount":73},[],{"intervention":90,"totalTrials":24,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":680,"PHASE4":682,"NA":684},{"trials":633,"activeCount":73},[],{"trials":635,"activeCount":73},[],{"trials":637,"activeCount":73},[638,642,646,658,670],{"nctId":79,"briefTitle":80,"status":81,"phases":639,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":640,"interventions":641},[63],[88],[69,39,69,39,90],{"nctId":92,"briefTitle":93,"status":81,"phases":643,"primaryCompletion":95,"completion":95,"start":96,"enrollment":97,"conditions":644,"interventions":645},[63],[99],[101,69,39,90,102],{"nctId":647,"briefTitle":648,"status":81,"phases":649,"primaryCompletion":650,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":656},"NCT00861120","Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type",[63],"2011-08","2012-08","2009-04",33,[655],"Epithelial Ovarian Cancer",[657,90],"Pegylated liposomal doxorubicin",{"nctId":659,"briefTitle":660,"status":499,"phases":661,"primaryCompletion":662,"completion":663,"start":664,"enrollment":219,"conditions":665,"interventions":667},"NCT01038037","First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer",[63],"2013-06","2013-12","2010-01",[666],"Non Small Cell Lung Cancer",[233,668,669],"Vinorelbine","panitumumab",{"nctId":671,"briefTitle":672,"status":81,"phases":673,"primaryCompletion":674,"completion":650,"start":675,"enrollment":676,"conditions":677,"interventions":678},"NCT00792363","Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations",[63],"2010-12","2008-11",32,[26],[679,90],"Irinotecan",{"trials":681,"activeCount":73},[],{"trials":683,"activeCount":73},[],{"trials":685,"activeCount":73},[],{"intervention":687,"totalTrials":408,"cells":688},"Veliparib",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":690,"activeCount":73},[],{"trials":692,"activeCount":73},[],{"trials":694,"activeCount":73},[695,704],{"nctId":696,"briefTitle":697,"status":81,"phases":698,"primaryCompletion":503,"completion":699,"start":422,"enrollment":700,"conditions":701,"interventions":703},"NCT01472783","Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation",[62,63],"2016-08",49,[702],"Recurrent, Epithelial Ovarian Cancer",[687],{"nctId":705,"briefTitle":706,"status":81,"phases":707,"primaryCompletion":437,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":712},"NCT01690598","Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status",[62,63],"2015-02","2012-11",22,[20],[687,713],"Topotecan",{"trials":715,"activeCount":73},[],{"trials":717,"activeCount":73},[],{"trials":719,"activeCount":73},[],{"intervention":721,"totalTrials":408,"cells":722},"bortezomib",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":724,"activeCount":73},[],{"trials":726,"activeCount":73},[],{"trials":728,"activeCount":73},[729,737],{"nctId":730,"briefTitle":731,"status":81,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":241,"conditions":735,"interventions":736},"NCT00436059","The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)",[63],"2009-07","2007-02",[23],[721],{"nctId":417,"briefTitle":418,"status":81,"phases":738,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":739,"interventions":740},[63],[23],[426,427,407,428,429],{"trials":742,"activeCount":73},[],{"trials":744,"activeCount":73},[],{"trials":746,"activeCount":73},[],{"intervention":679,"totalTrials":408,"cells":748},{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":750,"activeCount":73},[],{"trials":752,"activeCount":73},[],{"trials":754,"activeCount":73},[755,766],{"nctId":756,"briefTitle":757,"status":81,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":764},"NCT00827684","Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations",[63],"2011-01","2011-06","2009-03",50,[26],[679,765],"Temsirolimus",{"nctId":671,"briefTitle":672,"status":81,"phases":767,"primaryCompletion":674,"completion":650,"start":675,"enrollment":676,"conditions":768,"interventions":769},[63],[26],[679,90],{"trials":771,"activeCount":73},[],{"trials":773,"activeCount":73},[],{"trials":775,"activeCount":73},[],{"intervention":777,"totalTrials":408,"cells":778},"Cabazitaxel",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":780,"activeCount":73},[],{"trials":782,"activeCount":73},[],{"trials":784,"activeCount":73},[785,793],{"nctId":786,"briefTitle":787,"status":499,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":31,"conditions":791,"interventions":792},"NCT01747239","Cabazitaxel in Platinum Refractory Ovarian Cancer",[63],"2014-07","2013-01",[20],[777],{"nctId":794,"briefTitle":795,"status":81,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":802},"NCT02560337","Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.",[63],"2018-12-05","2019-06-01","2015-09",26,[20],[777],{"trials":804,"activeCount":73},[],{"trials":806,"activeCount":73},[],{"trials":808,"activeCount":73},[],{"intervention":101,"totalTrials":408,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":812,"activeCount":73},[],{"trials":814,"activeCount":73},[],{"trials":816,"activeCount":73},[817,821],{"nctId":92,"briefTitle":93,"status":81,"phases":818,"primaryCompletion":95,"completion":95,"start":96,"enrollment":97,"conditions":819,"interventions":820},[63],[99],[101,69,39,90,102],{"nctId":822,"briefTitle":823,"status":499,"phases":824,"primaryCompletion":650,"completion":825,"start":85,"enrollment":826,"conditions":827,"interventions":828},"NCT01109615","Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations",[63],"2012-03",40,[26],[829,101],"Pemetrexed",{"trials":831,"activeCount":73},[],{"trials":833,"activeCount":73},[],{"trials":835,"activeCount":73},[],{"intervention":233,"totalTrials":408,"cells":837},{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":839,"activeCount":73},[],{"trials":841,"activeCount":73},[],{"trials":843,"activeCount":73},[844,848],{"nctId":224,"briefTitle":225,"status":81,"phases":845,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":846,"interventions":847},[63],[20],[102,233],{"nctId":659,"briefTitle":660,"status":499,"phases":849,"primaryCompletion":662,"completion":663,"start":664,"enrollment":219,"conditions":850,"interventions":851},[63],[666],[233,668,669],{"trials":853,"activeCount":73},[],{"trials":855,"activeCount":73},[],{"trials":857,"activeCount":73},[],{"intervention":668,"totalTrials":408,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":861,"activeCount":73},[],{"trials":863,"activeCount":73},[],{"trials":865,"activeCount":73},[866,870],{"nctId":659,"briefTitle":660,"status":499,"phases":867,"primaryCompletion":662,"completion":663,"start":664,"enrollment":219,"conditions":868,"interventions":869},[63],[666],[233,668,669],{"nctId":871,"briefTitle":872,"status":81,"phases":873,"primaryCompletion":874,"completion":875,"start":876,"enrollment":16,"conditions":877,"interventions":878},"NCT01242449","Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer",[63],"2012-10","2014-10","2010-11",[18],[879,668],"Trastuzumab",{"trials":881,"activeCount":73},[],{"trials":883,"activeCount":73},[],{"trials":885,"activeCount":73},[],{"intervention":887,"totalTrials":112,"cells":888},"Gemcitabine, Oxaliplatin, Capecitabine,",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":890,"activeCount":73},[],{"trials":892,"activeCount":73},[],{"trials":894,"activeCount":73},[895],{"nctId":896,"briefTitle":897,"status":81,"phases":898,"primaryCompletion":95,"completion":95,"start":899,"enrollment":900,"conditions":901,"interventions":902},"NCT00779454","Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma",[63],"2008-09",72,[99],[887,903],"Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine",{"trials":905,"activeCount":73},[],{"trials":907,"activeCount":73},[],{"trials":909,"activeCount":73},[],{"intervention":903,"totalTrials":112,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":913,"activeCount":73},[],{"trials":915,"activeCount":73},[],{"trials":917,"activeCount":73},[918],{"nctId":896,"briefTitle":897,"status":81,"phases":919,"primaryCompletion":95,"completion":95,"start":899,"enrollment":900,"conditions":920,"interventions":921},[63],[99],[887,903],{"trials":923,"activeCount":73},[],{"trials":925,"activeCount":73},[],{"trials":927,"activeCount":73},[],{"intervention":765,"totalTrials":112,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":931,"activeCount":73},[],{"trials":933,"activeCount":73},[],{"trials":935,"activeCount":73},[936],{"nctId":756,"briefTitle":757,"status":81,"phases":937,"primaryCompletion":759,"completion":760,"start":761,"enrollment":762,"conditions":938,"interventions":939},[63],[26],[679,765],{"trials":941,"activeCount":73},[],{"trials":943,"activeCount":73},[],{"trials":945,"activeCount":73},[],{"intervention":947,"totalTrials":112,"cells":948},"Zoledronic Acid",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":963,"PHASE4":965,"NA":967},{"trials":950,"activeCount":73},[],{"trials":952,"activeCount":73},[],{"trials":954,"activeCount":73},[955],{"nctId":956,"briefTitle":957,"status":81,"phases":958,"primaryCompletion":959,"completion":959,"start":960,"enrollment":332,"conditions":961,"interventions":962},"NCT00760370","Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer",[63],"2011-12","2008-12",[23,18],[947],{"trials":964,"activeCount":73},[],{"trials":966,"activeCount":73},[],{"trials":968,"activeCount":73},[],{"intervention":970,"totalTrials":112,"cells":971},"Irinotecan 165 mg\u002Fm2 iv",{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":973,"activeCount":73},[],{"trials":975,"activeCount":73},[],{"trials":977,"activeCount":73},[978],{"nctId":979,"briefTitle":980,"status":81,"phases":981,"primaryCompletion":982,"completion":983,"start":984,"enrollment":985,"conditions":986,"interventions":987},"NCT02705300","Side Effects to FOLFOXIRI + Tocotrienol\u002FPlacebo as First Line Treatment of Metastatic Colorectal Cancer",[63],"2019-08","2024-03-27","2016-05-06",70,[15],[970,988,989,990],"Oxaliplatin 85 mg\u002Fm2 iv","Calcium folinate 200 mg\u002Fm2 iv","5-fluorouracil 3200 mg\u002Fm2",{"trials":992,"activeCount":73},[],{"trials":994,"activeCount":73},[],{"trials":996,"activeCount":73},[],{"intervention":988,"totalTrials":112,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":1000,"activeCount":73},[],{"trials":1002,"activeCount":73},[],{"trials":1004,"activeCount":73},[1005],{"nctId":979,"briefTitle":980,"status":81,"phases":1006,"primaryCompletion":982,"completion":983,"start":984,"enrollment":985,"conditions":1007,"interventions":1008},[63],[15],[970,988,989,990],{"trials":1010,"activeCount":73},[],{"trials":1012,"activeCount":73},[],{"trials":1014,"activeCount":73},[],{"intervention":989,"totalTrials":112,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1018,"activeCount":73},[],{"trials":1020,"activeCount":73},[],{"trials":1022,"activeCount":73},[1023],{"nctId":979,"briefTitle":980,"status":81,"phases":1024,"primaryCompletion":982,"completion":983,"start":984,"enrollment":985,"conditions":1025,"interventions":1026},[63],[15],[970,988,989,990],{"trials":1028,"activeCount":73},[],{"trials":1030,"activeCount":73},[],{"trials":1032,"activeCount":73},[],{"intervention":990,"totalTrials":112,"cells":1034},{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1036,"activeCount":73},[],{"trials":1038,"activeCount":73},[],{"trials":1040,"activeCount":73},[1041],{"nctId":979,"briefTitle":980,"status":81,"phases":1042,"primaryCompletion":982,"completion":983,"start":984,"enrollment":985,"conditions":1043,"interventions":1044},[63],[15],[970,988,989,990],{"trials":1046,"activeCount":73},[],{"trials":1048,"activeCount":73},[],{"trials":1050,"activeCount":73},[],{"intervention":1052,"totalTrials":112,"cells":1053},"Gemcitabine + Capecitabine",{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1055,"activeCount":73},[],{"trials":1057,"activeCount":73},[],{"trials":1059,"activeCount":73},[1060],{"nctId":1061,"briefTitle":1062,"status":81,"phases":1063,"primaryCompletion":355,"completion":420,"start":1064,"enrollment":700,"conditions":1065,"interventions":1066},"NCT01472770","A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer",[63],"2011-10",[26],[1052],{"trials":1068,"activeCount":73},[],{"trials":1070,"activeCount":73},[],{"trials":1072,"activeCount":73},[],{"intervention":713,"totalTrials":112,"cells":1074},{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1076,"activeCount":73},[],{"trials":1078,"activeCount":73},[],{"trials":1080,"activeCount":73},[1081],{"nctId":705,"briefTitle":706,"status":81,"phases":1082,"primaryCompletion":437,"completion":708,"start":709,"enrollment":710,"conditions":1083,"interventions":1084},[62,63],[20],[687,713],{"trials":1086,"activeCount":73},[],{"trials":1088,"activeCount":73},[],{"trials":1090,"activeCount":73},[],{"intervention":1092,"totalTrials":112,"cells":1093},"Epirubicin 90 mg\u002Fm2 iv",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1095,"activeCount":73},[],{"trials":1097,"activeCount":73},[],{"trials":1099,"activeCount":73},[1100],{"nctId":1101,"briefTitle":1102,"status":81,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1108},"NCT02909751","Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer",[63],"2019-01-21","2016-09-14",80,[18],[1092,1109,1110,1111,1112],"Cyclophosphamide 600 mg\u002Fm2 iv","Docetaxel 100 mg\u002Fm2 iv OR paclitaxel 80 mg\u002Fm2 iv","Trastuzumab 8 mg\u002Fkg iv saturation, then 6 mg\u002Fkg iv","Pertuzumab 840 mg iv saturation, then 420 mg iv",{"trials":1114,"activeCount":73},[],{"trials":1116,"activeCount":73},[],{"trials":1118,"activeCount":73},[],{"intervention":1109,"totalTrials":112,"cells":1120},{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1122,"activeCount":73},[],{"trials":1124,"activeCount":73},[],{"trials":1126,"activeCount":73},[1127],{"nctId":1101,"briefTitle":1102,"status":81,"phases":1128,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1129,"interventions":1130},[63],[18],[1092,1109,1110,1111,1112],{"trials":1132,"activeCount":73},[],{"trials":1134,"activeCount":73},[],{"trials":1136,"activeCount":73},[],{"intervention":1110,"totalTrials":112,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":73},[],{"trials":1142,"activeCount":73},[],{"trials":1144,"activeCount":73},[1145],{"nctId":1101,"briefTitle":1102,"status":81,"phases":1146,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1147,"interventions":1148},[63],[18],[1092,1109,1110,1111,1112],{"trials":1150,"activeCount":73},[],{"trials":1152,"activeCount":73},[],{"trials":1154,"activeCount":73},[],{"intervention":1111,"totalTrials":112,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":73},[],{"trials":1160,"activeCount":73},[],{"trials":1162,"activeCount":73},[1163],{"nctId":1101,"briefTitle":1102,"status":81,"phases":1164,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1165,"interventions":1166},[63],[18],[1092,1109,1110,1111,1112],{"trials":1168,"activeCount":73},[],{"trials":1170,"activeCount":73},[],{"trials":1172,"activeCount":73},[],{"intervention":1112,"totalTrials":112,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":73},[],{"trials":1178,"activeCount":73},[],{"trials":1180,"activeCount":73},[1181],{"nctId":1101,"briefTitle":1102,"status":81,"phases":1182,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1183,"interventions":1184},[63],[18],[1092,1109,1110,1111,1112],{"trials":1186,"activeCount":73},[],{"trials":1188,"activeCount":73},[],{"trials":1190,"activeCount":73},[],{"intervention":657,"totalTrials":112,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":73},[],{"trials":1196,"activeCount":73},[],{"trials":1198,"activeCount":73},[1199],{"nctId":647,"briefTitle":648,"status":81,"phases":1200,"primaryCompletion":650,"completion":651,"start":652,"enrollment":653,"conditions":1201,"interventions":1202},[63],[655],[657,90],{"trials":1204,"activeCount":73},[],{"trials":1206,"activeCount":73},[],{"trials":1208,"activeCount":73},[],{"intervention":222,"totalTrials":112,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":73},[],{"trials":1214,"activeCount":73},[],{"trials":1216,"activeCount":73},[1217],{"nctId":215,"briefTitle":216,"status":81,"phases":1218,"primaryCompletion":218,"completion":218,"start":84,"enrollment":219,"conditions":1219,"interventions":1220},[63],[20],[102,222],{"trials":1222,"activeCount":73},[],{"trials":1224,"activeCount":73},[],{"trials":1226,"activeCount":73},[],{"intervention":426,"totalTrials":112,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1239,"PHASE4":1241,"NA":1243},{"trials":1230,"activeCount":73},[],{"trials":1232,"activeCount":73},[],{"trials":1234,"activeCount":73},[1235],{"nctId":417,"briefTitle":418,"status":81,"phases":1236,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1237,"interventions":1238},[63],[23],[426,427,407,428,429],{"trials":1240,"activeCount":73},[],{"trials":1242,"activeCount":73},[],{"trials":1244,"activeCount":73},[],{"intervention":429,"totalTrials":112,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1248,"activeCount":73},[],{"trials":1250,"activeCount":73},[],{"trials":1252,"activeCount":73},[1253],{"nctId":417,"briefTitle":418,"status":81,"phases":1254,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":1255,"interventions":1256},[63],[23],[426,427,407,428,429],{"trials":1258,"activeCount":73},[],{"trials":1260,"activeCount":73},[],{"trials":1262,"activeCount":73},[],{"intervention":879,"totalTrials":112,"cells":1264},{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1266,"activeCount":73},[],{"trials":1268,"activeCount":73},[],{"trials":1270,"activeCount":73},[1271],{"nctId":871,"briefTitle":872,"status":81,"phases":1272,"primaryCompletion":874,"completion":875,"start":876,"enrollment":16,"conditions":1273,"interventions":1274},[63],[18],[879,668],{"trials":1276,"activeCount":73},[],{"trials":1278,"activeCount":73},[],{"trials":1280,"activeCount":73},[],{"intervention":1282,"totalTrials":112,"cells":1283},"Simvastatine",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1285,"activeCount":73},[],{"trials":1287,"activeCount":73},[],{"trials":1289,"activeCount":73},[1290],{"nctId":1291,"briefTitle":1292,"status":81,"phases":1293,"completion":1294,"start":1295,"enrollment":16,"conditions":1296,"interventions":1297},"NCT00281476","The Effect of High Dose Simvastatine on Multiple Myeloma",[62,63],"2007-11","2006-02",[23],[1282],{"trials":1299,"activeCount":73},[],{"trials":1301,"activeCount":73},[],{"trials":1303,"activeCount":73},[],{"intervention":1305,"totalTrials":112,"cells":1306},"Based on sensitivity analysis",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1308,"activeCount":73},[],{"trials":1310,"activeCount":73},[],{"trials":1312,"activeCount":73},[1313],{"nctId":1314,"briefTitle":1315,"status":81,"phases":1316,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":1320,"conditions":1321,"interventions":1322},"NCT03251612","Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer",[63],"2021-08-23","2022-03-21","2017-09-22",90,[109],[1305],{"trials":1324,"activeCount":73},[],{"trials":1326,"activeCount":73},[],{"trials":1328,"activeCount":73},[],{"intervention":829,"totalTrials":112,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1332,"activeCount":73},[],{"trials":1334,"activeCount":73},[],{"trials":1336,"activeCount":73},[1337],{"nctId":822,"briefTitle":823,"status":499,"phases":1338,"primaryCompletion":650,"completion":825,"start":85,"enrollment":826,"conditions":1339,"interventions":1340},[63],[26],[829,101],{"trials":1342,"activeCount":73},[],{"trials":1344,"activeCount":73},[],{"trials":1346,"activeCount":73},[],{"intervention":1348,"totalTrials":112,"cells":1349},"Experimental drug",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1351,"activeCount":73},[],{"trials":1353,"activeCount":73},[],{"trials":1355,"activeCount":73},[],{"trials":1357,"activeCount":73},[],{"trials":1359,"activeCount":73},[],{"trials":1361,"activeCount":73},[1362],{"nctId":1363,"briefTitle":1364,"status":81,"phases":1365,"primaryCompletion":1366,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT03821870","Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity",[],"2021-12-31","2023-02-22","2019-02-25",12,[1371],"Metastatic Pancreatic Cancer",[1348],{"intervention":1374,"totalTrials":112,"cells":1375},"corticosteroid",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1377,"activeCount":73},[],{"trials":1379,"activeCount":73},[],{"trials":1381,"activeCount":73},[],{"trials":1383,"activeCount":73},[],{"trials":1385,"activeCount":73},[],{"trials":1387,"activeCount":73},[1388],{"nctId":1389,"briefTitle":1390,"status":81,"phases":1391,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":97,"conditions":1394,"interventions":1396},"NCT02629783","Psychomotor Therapy as Complimentary Treatment to Patients With Shoulder Pain.",[66],"2017-09-01","2016-03-01",[1395],"Shoulder Pain",[1374]]